Thomas J. Jensen
Title | Associate Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
|
|
|
Bibliographic
-
Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, Rasmussen S, Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab. 2024 Mar; 26(3):1129-1132. PMID: 38082468.
-
Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovsk? V, Abhayaratna W, Kitzman DW. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024 01 16; 149(3):204-216. PMID: 37952180.
-
Andres-Hernando A, Jensen TJ, Kuwabara M, Orlicky DJ, Cicerchi C, Li N, Roncal-Jimenez CA, Garcia GE, Ishimoto T, Maclean PS, Bjornstad P, Sanchez-Lozada LG, Kanbay M, Nakagawa T, Johnson RJ, Lanaspa MA. Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. JCI Insight. 2021 01 11; 6(1). PMID: 33320834.
-
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110. PMID: 32647053.
-
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 08; 41(8):1663-1671. PMID: 29898902.
-
Ahr?n B, Hirsch IB, Pieber TR, Mathieu C, G?mez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016 Oct; 39(10):1693-701. PMID: 27493132.
-
van den Brink W, Strang J, Gual A, S?rensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015 Apr; 14(4):495-504. PMID: 25652768.
-
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Under-reporting of adverse effects of tesofensine. Lancet. 2013 Jul 13; 382(9887):127. PMID: 23849924.
-
Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun; 32(6):1205-20. PMID: 20637972.
-
Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Astrup A. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]. Ugeskr Laeger. 2009 Oct 05; 171(41):2974-7. PMID: 19824222.
-
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 11 29; 372(9653):1906-1913. PMID: 18950853.
-
Bloch Thomsen PE, Joergensen RM, Kanters JK, Jensen TJ, Haarbo J, Hagemann A, Vestergaard A, Saermark K. Phase 2 reentry in man. Heart Rhythm. 2005 Aug; 2(8):797-803. PMID: 16051112.
-
Jensen TJ, Haarbo J, Pehrson SM, Thomsen B. Impact of premature atrial contractions in atrial fibrillation. Pacing Clin Electrophysiol. 2004 Apr; 27(4):447-52. PMID: 15078396.
-
Jensen TJ, Haarbo J, Pehrson SM, Thomsen PE. Paroxysmal atrial fibrillation: ectopic atrial activity and prevalence of severely symptomatic patients. Pacing Clin Electrophysiol. 2003 Aug; 26(8):1668-74. PMID: 12877698.
-
Andersen NH, N?rgaard A, Jensen TJ, Ulstrup J. Sequential unfolding of the two-domain protein Pseudomonas stutzeri cytochrome c(4). J Inorg Biochem. 2002 Feb; 88(3-4):316-27. PMID: 11897346.
-
Hansen CN, Jensen TJ, Borch-Johnsen K. [Dyslipidemia, diabetes and cardiovascular disease]. Ugeskr Laeger. 2000 Aug 14; 162(33):4367-70. PMID: 10962957.
-
Deckert T, Yokoyama H, Mathiesen ER, R?nn B, Jensen TJ, Feldt-Rasmussen BF, Borch-Johnsen K, Jensen JS. [Microalbuminuria as predictor of atherosclerotic cardiovascular disease in IDDM]. Ugeskr Laeger. 1997 May 12; 159(20):3010-4. PMID: 9190730.
-
Jensen TJ, Hilsted JC. [Pharmacological prevention of late complications of diabetes]. Ugeskr Laeger. 1996 Apr 22; 158(17):2402-3. PMID: 8685997.
-
Skovby F, Dyerberg J, Faergeman O, Haghfelt T, Jensen TJ, Leth A, Sigurd B, Stender S, Vittrup MA. [Hyperlipidemia in children]. Ugeskr Laeger. 1993 Mar 15; 155(11):810-4. PMID: 8460436.
-
Dyerberg J, Stender S, Andersen GE, Faergeman O, Haghfelt T, Hviid T, Jensen TJ, Leth A, Sigurd B, Skovby F. [Recommendations for clinical-chemical departments: lipid-lipoprotein analysis]. Ugeskr Laeger. 1990 May 14; 152(20):1434-7. PMID: 2343500.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1996 | 1 | 1997 | 1 | 2000 | 1 | 2002 | 1 | 2003 | 1 | 2004 | 1 | 2005 | 1 | 2008 | 1 | 2009 | 1 | 2010 | 1 | 2013 | 1 | 2015 | 1 | 2016 | 1 | 2018 | 1 | 2020 | 1 | 2021 | 1 | 2023 | 2 |
To return to the timeline, click here.
|
Jensen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|